N
NeuVasQ Biotechnologies
Developing pharmaceuticals to restore blood-brain barrier function in acute neurological disorders such as stroke, epilepsy, and neurodegenerative diseases like Alzheimer’s
About NeuVasQ Biotechnologies
NeuVasQ Biotechnologies is a biopharmaceutical company focused on developing treatments for neurological disorders by restoring the integrity of the blood-brain and blood-retina barriers. The company was founded in 2021 as a spin-off from the Université Libre de Bruxelles (ULB) and is headquartered in Gosselies, Belgium.
The company's scientific foundation is based on the research of its founder, Professor Benoît Vanhollebeke, Director of the Laboratory of Neurovascular Signaling at ULB. His work centers on the molecular mechanisms that form and maintain the blood-brain barrier (BBB), particularly the role of the Wnt signaling pathway. Instead of trying to bypass the BBB to deliver drugs, NeuVasQ's approach is to repair the barrier itself, which can become permeable due to age or injury, leading to various neurological conditions.
NeuVasQ is pioneering first-in-class antibodies that target Gpr124 and Reck, proteins that act as cofactors in Wnt signaling, to selectively restore neurovascular function. This technology has potential applications for a range of conditions, including acute neurological disorders like stroke and epilepsy, neurodegenerative diseases such as Alzheimer's and Parkinson's, and vascular retinopathies like diabetic macular edema.
The company's business model is centered on research and development, with the goal of licensing its proprietary technologies and drug candidates to larger pharmaceutical partners. In June 2021, NeuVasQ secured approximately $24 million (€20 million) in a Series A funding round. The round was led by Newton Biocapital and included participation from public and private investors such as SFPI-FPIM, SRIW Life Sciences, and Theodorus, the ULB spin-off investment fund. In September 2022, Emmanuel Lacroix, a former Vice President at UCB Ventures, was appointed as CEO to lead the company through its next stage of development.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2021 | $22M | $88M | SFPIM · Wallonie Entreprendre · Newton BioCapital · Sambrinvest | ↗ |
| SPINOUT✓Other financing | Feb 2021 | $0 | — | Université libre de Bruxelles | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for NeuVasQ Biotechnologies is 850 monthly website visits, up 8400% over the last three months. NeuVasQ Biotechnologies's team grew 7.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NeuVasQ Biotechnologies in the Charleroi ecosystem
The NeuVasQ Biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Newton BioCapital
SFPIM
Wallonie Entreprendre
Sambrinvest
WE Venture
Other known investors2 additional known investors
Université libre de Bruxelles
Seido Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuVasQ Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuVasQ Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










